tetano
Editor, Senior Moderator
Dermatopathology (Basel)
. 2021 Sep 27;8(4):463-476.
doi: 10.3390/dermatopathology8040049.
Single-Center Clinico-Pathological Case Study of 19 Patients with Cutaneous Adverse Reactions Following COVID-19 Vaccines
Dennis Niebel[SUP] 1 [/SUP], Joerg Wenzel[SUP] 1 [/SUP], Dagmar Wilsmann-Theis[SUP] 1 [/SUP], Jana Ziob[SUP] 1 [/SUP], Jasmin Wilhelmi[SUP] 1 [/SUP], Christine Braegelmann[SUP] 1 [/SUP]
Affiliations
Abstract
(1) Background: Coronavirus disease 2019 (COVID-19) vaccines are currently employed on a population-wide scale in most countries worldwide. Data about unusual cutaneous adverse drug reactions (ADR) are scant, though. (2) Methods: We retrospectively analyzed moderate to severe vaccine-related ADR in the Department of Dermatology and Allergy of the University Hospital Bonn between May to June 2021 and analyzed related skin biopsies. (3) Results: As a specialized dermatological academic center, we encountered a total of n = 19 clinically and pathologically heterogeneous cutaneous ADR with a female predominance. Delayed cutaneous ADR occurred as late as 30 days after vaccination. The majority of ADR were mild, though a few patients required systemic treatment (antihistamines, glucocorticosteroids). (4) Conclusions: The clinico-pathological spectrum of cutaneous side effects with COVID-19 vaccines is wide; however, the benefits outweigh the risks by far. More dermatopathological studies on cutaneous ADR not limited to COVID-19 vaccines are desirable to enable a better understanding of underlying pathophysiological mechanisms.
Keywords: COVID-19; adverse event; drug reaction; eosinophilia; interface dermatitis.
. 2021 Sep 27;8(4):463-476.
doi: 10.3390/dermatopathology8040049.
Single-Center Clinico-Pathological Case Study of 19 Patients with Cutaneous Adverse Reactions Following COVID-19 Vaccines
Dennis Niebel[SUP] 1 [/SUP], Joerg Wenzel[SUP] 1 [/SUP], Dagmar Wilsmann-Theis[SUP] 1 [/SUP], Jana Ziob[SUP] 1 [/SUP], Jasmin Wilhelmi[SUP] 1 [/SUP], Christine Braegelmann[SUP] 1 [/SUP]
Affiliations
- PMID: 34698094
- DOI: 10.3390/dermatopathology8040049
Abstract
(1) Background: Coronavirus disease 2019 (COVID-19) vaccines are currently employed on a population-wide scale in most countries worldwide. Data about unusual cutaneous adverse drug reactions (ADR) are scant, though. (2) Methods: We retrospectively analyzed moderate to severe vaccine-related ADR in the Department of Dermatology and Allergy of the University Hospital Bonn between May to June 2021 and analyzed related skin biopsies. (3) Results: As a specialized dermatological academic center, we encountered a total of n = 19 clinically and pathologically heterogeneous cutaneous ADR with a female predominance. Delayed cutaneous ADR occurred as late as 30 days after vaccination. The majority of ADR were mild, though a few patients required systemic treatment (antihistamines, glucocorticosteroids). (4) Conclusions: The clinico-pathological spectrum of cutaneous side effects with COVID-19 vaccines is wide; however, the benefits outweigh the risks by far. More dermatopathological studies on cutaneous ADR not limited to COVID-19 vaccines are desirable to enable a better understanding of underlying pathophysiological mechanisms.
Keywords: COVID-19; adverse event; drug reaction; eosinophilia; interface dermatitis.